{
    "eid": "2-s2.0-85125207360",
    "title": "Clinical Outcomes and Safety of Secukinumab in Thai Patients with Plaque Psoriasis: A 16-Week, Multicenter, Retrospective, Real-World Study",
    "cover-date": "2022-02-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Medicine (all)",
            "@code": "2700",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Clinical outcomes",
        "Psoriasis",
        "Real-world",
        "Safety",
        "Secukinumab"
    ],
    "authors": [
        "Bensachee Pattamadilok",
        "Pravit Asawanonda",
        "Charoen Choonhakarn",
        "Chanidapa Wongtada",
        "Ploysyne Rattanakaemakorn",
        "Natta Rajatanavin"
    ],
    "citedby-count": 0,
    "ref-count": 29,
    "ref-list": [
        "The global state of psoriasis disease epidemiology: A workshop report",
        "Psoriasis",
        "Psoriasis pathogenesis and treatment",
        "Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: A systematic review and network meta-analysis of randomized controlled trials",
        "Pathogenesis and clinical features of psoriasis",
        "Quality of life in patients with psoriasis: A systematic literature review",
        "Secukinumab in plaque psoriasis-results of two phase 3 trials",
        "Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity",
        "The emerging role of IL-17 in the pathogenesis of psoriasis: Preclinical and clinical findings",
        "Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: Implications for psoriasis pathogenesis",
        "The IL-17 family of cytokines in psoriasis: IL-17A and beyond",
        "IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis",
        "Secukinumab: Review of clinical evidence from the pivotal studies ERASURE, FIXTURE, and CLEAR",
        "Effectiveness and safety of secukinumab in Italian patients with psoriasis: An 84 week, multicenter, retrospective real-world study",
        "Limitations of current monoclonal antibodies for plaque-type psoriasis and an outlook for the future",
        "Secukinumab: First global approval",
        "Secukinumab: A review of the anti-IL-17A biologic for the treatment of psoriasis",
        "Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial",
        "In which patients the best efficacy of secukinumab?. Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis",
        "Realworld evidence of secukinumab in psoriasis treatment - a meta-analysis of 43 studies",
        "Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: Results from a European, multicentric, retrospective, real-world study",
        "Secukinumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study up to 52 weeks observation",
        "Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: A 52-week, multicenter, retrospective study in Spain",
        "Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis",
        "Profile of secukinumab in the treatment of psoriasis: Current perspectives",
        "Onset of action of biologics in patients with moderate-to-severe psoriasis",
        "Secukinumab for psoriasis in obese patients: Minireview and clinical experience",
        "Secukinumab in the Treatment of Palmoplantar, Nail, Scalp, and Pustular Psoriasis",
        "Secukinumab in the treatment of psoriasis: Patient selection and perspectives"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60199578",
            "affilname": "Ramathibodi Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199578",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Khon Kaen",
            "@id": "60017165",
            "affilname": "Khon Kaen University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017165",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nontaburi",
            "@id": "60015728",
            "affilname": "Thailand Ministry of Public Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015728",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}